HopeStage
Back to all studies
CompletedNCT04127058

Iloperidone Dose Schedule for Bipolarity or Schizophrenia

About this title

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Read the official source — NCT04127058
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
MarltonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 7, 2019
Recruitment status
Completed
Enrollment listed in the registry
12
Sponsor
Vanda Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04127058
Official title
Show the full official title

A Safety/Tolerance Study to Evaluate a New Titration Scheme in Patients With Bipolar I Disorder or Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Marlton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Vanda Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including Iloperidone.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies